Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Current Assets (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Current Assets for 7 consecutive years, with $245.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets fell 40.11% to $245.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $245.6 million, a 40.11% decrease, with the full-year FY2024 number at $362.3 million, down 28.34% from a year prior.
  • Current Assets was $245.6 million for Q3 2025 at Pliant Therapeutics, down from $311.2 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $588.2 million in Q1 2023 to a low of $173.5 million in Q2 2022.
  • A 5-year average of $343.2 million and a median of $311.2 million in 2025 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: soared 226.0% in 2023, then tumbled 40.11% in 2025.
  • Pliant Therapeutics' Current Assets stood at $209.4 million in 2021, then soared by 62.49% to $340.3 million in 2022, then surged by 48.54% to $505.5 million in 2023, then dropped by 28.34% to $362.3 million in 2024, then plummeted by 32.21% to $245.6 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Current Assets are $245.6 million (Q3 2025), $311.2 million (Q1 2025), and $362.3 million (Q4 2024).